Loading...
01/11 16:22
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a challenging scenario for Medifast, Inc. with significant declines in revenue, active coaches, and earnings. Despite some cost reduction efforts, the overall financial performance is weak, with missed EPS expectations and a negative outlook. The Q&A session revealed management's inability to provide clear guidance, further contributing to uncertainty. The absence of a share repurchase program and the lack of significant positive catalysts suggest a negative market reaction in the near term.
Revenue $115.7 million, a decrease of 33.8% year-over-year, primarily due to a decrease in the number of active earning OPTAVIA coaches.
Active Earning OPTAVIA Coaches Approximately 25,400, a decrease of 32.8% from Q1 2024.
Average Revenue per Active Earning OPTAVIA Coach $4,556, a year-over-year decrease of 1.4%, compared to a decrease of 22.8% during Q1 of 2024, driven by increased productivity of newer coach cohorts.
Gross Profit $84.2 million, a decrease of 33.8% year-over-year, driven by lower sales volumes.
Gross Profit Margin 72.8%, consistent with the year-earlier period.
SG&A Expense $85.5 million, down 28.4% year-over-year, primarily due to a $22.4 million decrease in OPTAVIA coach compensation, $3 million on market research and investment costs that did not recur, a $2.5 million decrease in employee compensation, and a $1.3 million decrease in credit card fees.
SG&A as a Percentage of Revenue Increased 560 basis points, primarily due to loss of leverage of fixed costs and company-led marketing efforts.
Loss from Operations $1.3 million, down $9.2 million year-over-year, with the decline in gross profit largely offset by lower SG&A as a percentage of revenue.
Other Income $1.8 million, a decrease of 50.9% year-over-year, due to higher unrealized gains on investments in the prior year.
Income Tax Expense $1.3 million, lower than $3.3 million in the prior year, primarily driven by a decrease in pre-tax income.
Net Loss $0.8 million or $0.07 per share, compared to net income of $8.3 million or $0.76 per diluted share in the year earlier period.
Cash and Cash Equivalents $164.6 million, with no interest-bearing debt as of March 31, 2025.
New Product Launches: Over the past 18 months, Medifast has launched OPTAVIA ACTIVE for individuals wanting to incorporate exercise into their plans, and the OPTAVIA ASCEND line, designed for those using GLP-1 medications or transitioning into a weight management phase.
Product Development: Recent development breakthroughs are expected to enhance the effectiveness of the OPTAVIA Essential line and support the business transformation over the next 12 to 18 months.
Market Positioning: Medifast is focusing on the health and wellness space, particularly around weight loss and management, and believes it is well-positioned to take advantage of evolving trends.
Market Expansion: The company is enhancing its coach community and product offerings to better serve a growing and diverse customer base.
Operational Efficiencies: SG&A expenses decreased by 28.4% year-over-year to $85.5 million, primarily due to lower OPTAVIA coach compensation and reduced marketing costs.
Coach Productivity: The company has seen lower year-over-year declines in coach productivity, with a double-digit increase in new coaches compared to the same period last year.
Strategic Shifts: In 2025, Medifast is sharpening its focus on empowering coaches, streamlining their development path, and enhancing tools and insights available to them.
Business Model Focus: The company is shifting emphasis back to its coach community, which is central to its brand strength and program success.
Earnings Expectations: Medifast, Inc. missed earnings expectations with a reported EPS of $-0.11, compared to expectations of $-0.07.
Active Coaches Decline: The number of active earning OPTAVIA coaches decreased by 32.8% from the first quarter of 2024, impacting revenue significantly.
Revenue Decline: Revenue for Q1 2025 was $115.7 million, a decrease of 33.8% year-over-year, primarily due to the decrease in active coaches.
Economic Factors: A weaker economy could present consumer demand headwinds, although historical trends suggest economic slowdowns may increase coach recruitment.
SG&A Expenses: SG&A expenses decreased by 28.4% year-over-year, but the percentage of revenue increased due to lower sales volumes.
Market Research Costs: There was a significant decrease in market research and investment costs related to medically supported weight loss, which impacted the financials.
Investment Risks: Unrealized gains on investments in LifeMD common stock decreased by 50.9% year-over-year, indicating potential volatility in investment returns.
Regulatory Issues: The company does not currently expect tariffs to have any meaningful impact on its business this year.
Focus on Coaches: In 2025, Medifast is sharpening its focus on reigniting the coach community, simplifying the coaching experience, increasing productivity, and creating scalable businesses through stronger new customer acquisition and better retention.
Streamlining Coach Development: The company is streamlining the coach development path to help coaches succeed in a changed competitive environment, emphasizing building leadership skills and providing clearer guidance.
Enhancing Tools for Coaches: Medifast is enhancing digital business tools for coaches to track customer progress and tailor solutions, focusing on personalized customer service.
Broadening Product Offerings: The company is continuing to broaden its product offerings, including the OPTAVIA ACTIVE and ASCEND lines, to provide coaches with more tools to serve customers.
Investment in Development: Investment in new product developments is expected to be mitigated by reductions in company-led marketing costs.
Q2 Revenue Guidance: For the second quarter, Medifast expects revenue to range from $85 million to $105 million.
Q2 EPS Guidance: Loss per share for the second quarter is expected to range from $0.00 to $0.55.
Long-term Outlook: The company anticipates improvement in coach productivity in the second half of 2025 and coach growth in the second half of 2026.
Share Repurchase Program: None
The earnings call highlighted significant challenges, including a 36.2% revenue decline, increased SG&A expenses, and a net loss, indicating financial strain. Despite optimistic guidance on coach productivity and new programs, economic uncertainties and competition pose risks. The Q&A session revealed unclear management responses, adding to investor concerns. Although there are plans for product evolution and a focus on metabolic health, the lack of immediate positive catalysts and the absence of a market cap suggest a negative stock price movement in the short term.
The earnings call revealed significant challenges: a 37.4% revenue decline, reduced coach productivity, and client acquisition pressures. Despite cost optimizations and no debt, the market faces economic uncertainties and competitive challenges from GLP-1 medications. Q&A insights did not mitigate these concerns, as reliance on GLP-1 was noted. While operational improvements and investment gains led to positive net income, the weak revenue guidance and coach network issues indicate a negative short-term outlook, likely resulting in a stock price decline of -2% to -8%.
The earnings call presents a challenging scenario for Medifast, Inc. with significant declines in revenue, active coaches, and earnings. Despite some cost reduction efforts, the overall financial performance is weak, with missed EPS expectations and a negative outlook. The Q&A session revealed management's inability to provide clear guidance, further contributing to uncertainty. The absence of a share repurchase program and the lack of significant positive catalysts suggest a negative market reaction in the near term.
The earnings call reveals significant challenges: a 33.8% revenue decline, a 32.8% drop in active coaches, and a net loss of $800,000. Despite cost reductions, operational losses and weak guidance overshadow any positives. The Q&A highlights management's reluctance to provide clear guidance, adding uncertainty. The absence of a shareholder return plan and a decrease in marketing efforts further dampen outlook. These factors suggest a negative stock price reaction over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
